2023 연구성과 (9 / 285)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | Meeting Abstract | Fibrosis-4 and M2BPGi combination screening algorithm for screening advanced hepatic fibrosis in diabetes is cost-effective | Kim, Mimi; Jun, Dae Won; Kim, Hye-Lin; Yoon, Eileen; Jang, Se Young; Yoon, Ki Tae; Cho, Young Youn; Jo, Hoon Gil; Baek, Yang-Hyun; Moon, Sang Yi; Jo, Aejeong | Hanyang Univ, Coll Med, Seoul, South Korea; Sahmyook Univ, Coll Pharm, Seoul, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Daegu, South Korea; Pusan Natl Univ, Busan, South Korea; Chung Ang Univ Hosp, Seoul, South Korea; Wonkwang Univ, Coll Med & Hosp, Iksan, South Korea; Dong A Univ, Dept Internal Med, Coll Med, Busan, South Korea | Se Young, Jang/MTD-4362-2025; Jun, Dae Won/O-4529-2017; Kim, Chang/G-5001-2015 | noshin@hanyang.ac.kr; | JOURNAL OF HEPATOLOGY | J HEPATOL | 0168-8278 | 1600-0641 | 78 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2023 | 26.8 | 1.7 | 0 | English | 2023 | 2023-06 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | ○ | Article | High-performance self-powered color filter-free blue photodetector based on wide-bandgap halide perovskites | Blue photodetectors (PDs) are attracting great attention for various applications. Commercial blue PDs based on inorganic GaP or InGaN absorbers are limited by their expensive, complex, and high -temperature fabrication techniques. Organic absorber-based blue PDs still have much lower photode-tecting properties than inorganic blue PDs. In this study, a high-performance self-powered blue PD is developed using methylammonium lead halide (MAPbX3; X = I, Br, and Cl) perovskites based on the eco-nomic and facile solution process at low temperatures. Optimal composition is obtained through halide-composition engineering. Our best-performing device exhibits an average external quantum efficiency and an average detectivity of 42.7% and 8.65 x 10 11 Jones, respectively, within the blue region. The peak responsivity of the proposed PD is 0.174 A W -1 at 455 nm, which is comparable to that of commercial gallium phosphide blue PD (0.180 A W -1 at 470 nm). Moreover, the proposed device exhibits excellent en-vironmental stability under ambient air conditions. These findings will act as a basis for next-generation image sensor technologies, such as vertically stacked red/green/blue PDs.(c) 2023 Published by Elsevier Ltd on behalf of The editorial office of Journal of Materials Science & Technology. | Yun, Yeonghun; Cho, Hanbyeol; Jung, Jina; Yang, Sung Woong; Vidyasagar, Devthade; Gunasekaran, Rajendra Kumar; Lee, Sangwook | Kyungpook Natl Univ KNU, Sch Mat Sci & Engn, Daegu 41566, South Korea; Kyungpook Natl Univ, KNU Adv Mat Res Inst, Daegu 41566, South Korea; Karlsruhe Inst Technol, Inst Microstruct Technol, D-76131 Karlsruhe, Germany; Karlsruhe Inst Technol, Light Technol Inst, D-76131 Karlsruhe, Germany | ; Lee, Sangwook/O-9166-2015; Gunasekaran, Rajendra Kumar/ISU-5759-2023; Yun, Yeonghun/KRP-9208-2024; Vidyasagar, Devthade/O-3930-2015; JUNG, Jina/HMD-1392-2023 | 57202548363; 57215041777; 57222277455; 58055005400; 57201674442; 57201582809; 57203597324 | wook2@knu.ac.kr; | JOURNAL OF MATERIALS SCIENCE & TECHNOLOGY | J MATER SCI TECHNOL | 1005-0302 | 1941-1162 | 152 | SCIE | MATERIALS SCIENCE, MULTIDISCIPLINARY;METALLURGY & METALLURGICAL ENGINEERING | 2023 | 11.2 | 1.7 | 1.26 | 2025-06-25 | 10 | 10 | Perovskites; Photodetectors; Blue; Composition engineering; Self-powered; Wide bandgap | SOLAR-CELL; LIGHT; PHOTOLUMINESCENCE; ENERGY; ARRAY | Blue; Composition engineering; Perovskites; Photodetectors; Self-powered; Wide bandgap | Energy gap; Gallium alloys; Gallium phosphide; III-V semiconductors; Lead compounds; Perovskite; Photons; Semiconductor alloys; Blue; Color filters; Composition engineering; Fabrication technique; Halide perovskites; Highest temperature; Inorganics; Performance; Self-powered; Wide-band-gap; Photodetectors | English | 2023 | 2023-07-20 | 10.1016/j.jmst.2022.12.041 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study | PURPOSE To present primary and final analyses from the randomized, double-blind, placebo-controlled, phase III iNTEGRATE study, which evaluated the safety and efficacy of ibrutinib with prednisone in previously untreated patients with chronic graft-versus-host disease (cGVHD).METHODS Patients (age = 12 years) with newly diagnosed moderate or severe cGVHD, requiring systemic corticosteroid therapy, and with no prior systemic treatment for cGVHD were randomly assigned 1:1 to receive ibrutinib 420 mg once daily plus prednisone, starting at 1 mg/kg once daily or placebo plus prednisone. The primary end point was response rate at 48 weeks according to 2014 National Institutes of Health Consensus Development Project Criteria. Other end points included event-free survival, duration of response, time to withdrawal of immunosuppressants, improvement in Lee cGVHD Symptom Scale score, overall survival (OS), and safety.RESULTS Ninety-five and 98 patients enrolled in the ibrutinib-prednisone and placebo-prednisone arms, respectively. At 48 weeks, response rates were 41% (ibrutinib-prednisone) and 37% (placebo-prednisone; P = .54). At 33 months of follow-up, median duration of response was 19 months (ibrutinib-prednisone) and 10 months (placebo-prednisone; P = .10). Median event-free survival was 15 months (ibrutinib-prednisone) and 8 months (placebo-prednisone; hazard ratio, 0.76; 95% CI, 0.54 to 1.1; P = .11). Improvement in overall Lee cGVHD Symptom Scale was 43% (ibrutinib-prednisone) and 31% (placebo-ibrutinib; P = .07). Median OS was not reached in either arm. The 24-month Kaplan-Meier OS estimates were 80% for both arms (hazard ratio, 1.06; 95% CI, 0.59 to 1.90). Grade = 3 serious adverse events occurred in 49% (ibrutinib-prednisone) and 47% (placebo-prednisone) of patients.CONCLUSION There was no statistical difference observed in the primary and secondary end points with ibrutinib-prednisone treatment. No new safety signals were observed with ibrutinib treatment in previously untreated patients with cGVHD. The primary end point of iNTEGRATE was not met. | Miklos, David Bernard; Abu Zaid, Mohammad; Cooney, Julian P.; Albring, Joern C.; Flowers, Mary; Skarbnik, Alan P.; Yakoub-Agha, Ibrahim; Ko, Bor-Sheng; Bruno, Benedetto; Waller, Edmund K.; Yared, Jean; Sohn, Sang Kyun; Bulabois, Claude-Eric; Teshima, Takanori; Jacobsohn, David; Greinix, Hildegard; Mokatrin, Ahmad; Lee, Yihua; Wahlstrom, Justin T.; Styles, Lori; Socie, Gerard | Stanford Univ, Sch Med, Stanford, CA 94305 USA; Indiana Univ, Melvin & Bren Simon Canc Ctr IUSCC, Indianapolis, IN USA; Fiona Stanley Hosp, Murdoch, Australia; Univ Western Australia, Crawley, Australia; Univ Munster, Munster, Germany; Fred Hutchinson Canc Res Ctr, Seattle, WA USA; John Theurer Canc Ctr, Hackensack, NJ USA; Novant Hlth Canc Inst, Charlotte, NC USA; Univ Lille, CHU Lille, INSERM U1286, Infinite, Lille, France; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan; Natl Taiwan Univ, Dept Hematol Oncol, Canc Ctr, Taipei, Taiwan; Univ Torino, Dept Mol Biotechnol & Hlth Sci, Turin, Italy; Emory Univ, Winship Canc Inst, Atlanta, GA USA; Univ Maryland, Greenebaum Comprehens Canc Ctr, Sch Med, Baltimore, MD USA; Kyungpook Natl Univ Hosp, Daegu, South Korea; CHU Grenoble Alpes, La Tronche, France; Hokkaido Univ, Fac Med, Sapporo, Japan; Childrens Natl Hosp, Washington, DC USA; Med Univ Graz, Graz, Austria; AbbVie Co, Pharmacycl LLC, South San Francisco, CA USA; Hop St Louis, AP HP, Paris, France; Univ Paris, Paris, France | Abu Zaid, Mohammad/AFO-3625-2022; Bruno, Benedetto/K-1392-2018; SOCIE, Gerard/GPS-9152-2022; teshima, takanori/G-1671-2012; Waller, Edmund/AAP-3055-2020; Yakoub-Agha, Ibrahim/R-7872-2018 | 7003556550; 57195223634; 7102386892; 6506861097; 57190794279; 8309266900; 56350354100; 35210620900; 7006765099; 7005216765; 55192218800; 13310226800; 6602638654; 7102085240; 57207614755; 7005936353; 6505981559; 57201462329; 7102182374; 57207546452; 7102937268 | dmiklos@stanford.edu; | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 41 | 10 | SCIE | ONCOLOGY | 2023 | 42.1 | 1.7 | 4.69 | 2025-06-25 | 25 | 32 | CLINICAL-TRIALS; PREDNISONE; THERAPY; CYCLOSPORINE; THALIDOMIDE; INHIBITOR; SURVIVAL; FAILURE; BLOOD; CGVHD | Antineoplastic Combined Chemotherapy Protocols; Bronchiolitis Obliterans Syndrome; Child; Double-Blind Method; Humans; Piperidines; Prednisone; Progression-Free Survival; alanine aminotransferase; aspartate aminotransferase; ibrutinib; placebo; prednisone; antineoplastic agent; ibrutinib; piperidine derivative; prednisone; adolescent; adult; aged; alanine aminotransferase blood level; Article; aspartate aminotransferase blood level; atrial fibrillation; chronic graft versus host disease; constipation; corticosteroid therapy; coughing; diarrhea; drug efficacy; drug safety; dyspnea; event free survival; fatigue; female; fever; first-line treatment; follow up; heart arrest; human; hyperglycemia; hypertension; insomnia; major clinical study; male; muscle spasm; opportunistic infection; overall survival; peripheral edema; phase 3 clinical trial (topic); randomized controlled trial (topic); side effect; systemic therapy; thrombocytopenia; treatment response; upper respiratory tract infection; vomiting; child; clinical trial; controlled study; double blind procedure; phase 3 clinical trial; randomized controlled trial | English | 2023 | 2023-04-01 | 10.1200/jco.22.00509 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | Meeting Abstract | Incidence, landscape and survival outcome of de novo malignancy after double lung transplantation. | Chung, Liam Il-Young; Lee, Jeeyeon; Yang, Won Jun; Kim, Hye Sung; Lee, Yunjoo; Yu, Jisang; Bharat, Ankit; Chae, Young Kwang | Northwestern Univ, Feinberg Sch Med, Chicago, IL USA; Kyungpook Natl Univ Hosp, Daegu, South Korea; Northwestern Univ, Chicago, IL USA | Chung, Liam Il-Young/IQU-0821-2023; Kim, Hye Sung/LQV-0440-2024 | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 41 | 16 | SCIE | ONCOLOGY | 2023 | 42.1 | 1.7 | 0 | English | 2023 | 2023-06-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) | Yu, Jisang; Velichko, Yury; Kim, Hyeonseon; Gennaro, Nicolo; Soliman, Moataz; Kim, Leeseul; Oh, Youjin; Djunadi, Trie Arni; Lee, Jeeyeon; Chung, Liam Il-Young; Yoon, Sung Mi; Shah, Zunairah; Yang, Won Jun; Kim, Hye Sung; Lee, Yunjoo; Lee, Soowon; Kang, Daeun; Agrawal, Rishi; Aouad, Pascale; Chae, Young Kwang | Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Northwestern Med Dev Therapeut Inst, Chicago, IL USA; Northwestern Mem Hosp, Chicago, IL 60611 USA; AMITA Hlth St Francis Hosp Evanston, Evanston, IL USA; Kyungpook Natl Univ Hosp, Daegu, South Korea; Louis A Weiss Mem Hosp, Chicago, IL USA; Northwestern Univ, Chicago, IL 60611 USA; Semmelweis Egyet, Budapest, Hungary; Baylor Univ, Waco, TX 76798 USA; Northwestern Univ, Evanston, IL USA | Velichko, Yuri/D-8596-2011; Kim, Hye Sung/LQV-0440-2024; Gennaro, Nicolò/P-1776-2019; Chung, Liam Il-Young/IQU-0821-2023 | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 41 | 16 | SCIE | ONCOLOGY | 2023 | 42.1 | 1.7 | 0 | English | 2023 | 2023-06-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | MELK and Del-1 as druggable targets in TNBC. | Lee, In Hee; Lee, Soo Jung; Kang, Byeongju; Lee, Jeeyeon; Park, Ho Yong; Park, Ji-young; Park, Jee-Young Nora; Chae, Yee Soo | Kyungpook Natl Univ, Chilgok Hosp, Dept Hematol Oncol, Sch Med, Daegu, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Dept Oncol Hematol, Daegu, South Korea; Kyungpook Natl Univ Hosp, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Dept Surg, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Dept Pathol, Daegu, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Daegu, South Korea | Park, Jin-Young/HDN-0483-2022; PARK, JUN-YOUNG/P-5981-2015; Park, Jung Hwan/AAA-1951-2022 | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 41 | 16 | SCIE | ONCOLOGY | 2023 | 42.1 | 1.7 | 0 | English | 2023 | 2023-06-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial) | Jung, Ji-Jung; Kim, Soo-Yeon; Koh, Jiwon; Cheun, Jong-Ho; Kim, Min Kyoon; Ryu, Jai Min; Yoo, Tae-Kyung; Park, Seho; Shin, Hee-Chul; Ahn, Sung Gwe; Lim, Woosung; Nam, Sang Eun; Park, Min Ho; Lee, Jeeyeon; Kang, Taewoo; Kim, Ku Sang; Youn, Hyun Jo; Kim, Yoo Seok; Han, Wonshik; Lee, Han-Byoel | Seoul Natl Univ, Dept Surg, Coll Med, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Radiol, Seoul, South Korea; Seoul Natl Univ, Dept Pathol, Coll Med, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Radiol, Seoul, South Korea; Seoul Metropolitan Govt Seoul Natl Univ, Boramae Med Ctr, Dept Surg, Seoul, South Korea; Chung Ang Univ Hosp, Seoul, South Korea; Sungkyunkwan Univ, Div Breast Surg, Dept Surg, Samsung Med Ctr,Sch Med, Seoul, South Korea; Asan Med Ctr, Seoul, South Korea; Yonsei Univ, Div Breast Surg, Dept Surg, Yonsei Canc Ctr,Coll Med, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Surg, Bundang Hosp, Seoul, South Korea; Yonesi Univ, Gangnam Severance Hosp, Seoul, South Korea; Ewha Womans Univ, Med Ctr, Seoul, South Korea; Konkuk Univ, Sch Med, Breast Canc Ctr, Med Ctr, Seoul, South Korea; Chonnam Natl Univ, Med Sch, Dept Surg, Hwasun Hosp, Hwasun, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Surg, Daegu, South Korea; Pusan Natl Univ Hosp, Busan Canc Ctr, Biomed Res Inst, Breast Canc Clin, Busan, South Korea; Kosin Univ, Dept Surg, Gospel Hosp, Busan, South Korea; Jeonbuk Natl Univ, Dept Surg, Med Sch, Jeonju, South Korea; Chosun Univ, Dept Surg, Coll Med, Gwangju, South Korea; Seoul Natl Univ, Dept Surg, Coll Med, Seoul, South Korea | Ahn, Sung Gwe/AFD-8122-2022; Lee, Dong-Hyeon/AAM-3893-2021; Kim, Jee/J-5441-2012; Park, Seho/LUZ-3414-2024; KIM, SEON-OK/HGC-7012-2022; Kim, Sooyeon/AAA-8521-2022 | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 41 | 16 | SCIE | ONCOLOGY | 2023 | 42.1 | 1.7 | 6 | English | 2023 | 2023-06-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6) | Lee, Jung-Yun; Park, Junsik; Choi, Chel Hun; Cho, Hyun Woong; No, Jae Hong; Hong, Dae Gy | Yonsei Univ, Coll Med, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea; Korea Univ, Coll Med, Seoul, South Korea; Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea; Kyungpook Natl Univ, Sch Med, Daegu, South Korea | Choi, Youn/AAS-3301-2021; Park, Junsik/KIB-5533-2024; Lee, Yoon/ABA-8808-2020 | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 41 | 16 | SCIE | ONCOLOGY | 2023 | 42.1 | 1.7 | 0 | English | 2023 | 2023-06-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) | Lau, George; Cheng, Ann-Lii; Sangro, Bruno; Kudo, Masatoshi; Kelley, Robin Kate; Tak, Won Young; Gasbarrini, Antonio; Reig, Maria; Lim, Ho Yeong; Tougeron, David; De Toni, Enrico N.; Tam, Vincent C.; Mody, Kabir; Gong, Jun; Mccoy, Carrie L.; Gupta, Charu; Makowsky, Mallory; Negro, Alejandra; Abou-Alfa, Ghassan K. | Humanity & Hlth Med Grp, Humanity & Hlth Clin Trial Ctr, Hong Kong, Peoples R China; Natl Taiwan Univ, Natl Taiwan Univ Hosp, Canc Ctr, Taipei, Taiwan; Clin Univ Navarra, Liver Unit, Pamplona, Spain; Clin Univ Navarra, HPB Oncol Area, Pamplona, Spain; CIBEREHD, Pamplona, Spain; Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan; Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Univ Cattolica Sacro Cuore, Fdn Policlin Univ Gemelli IRCCS, Rome, Italy; Univ Barcelona, CIBEREHD, IDIBAPS, Hosp Clin Barcelona,Barcelona Clin Liver Canc, Barcelona, Spain; Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea; Univ Poitiers Hosp, Dept Gastroenterol, Poitiers, France; Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 2, Munich, Germany; Univ Calgary, Dept Oncol, Tom Baker Canc Ctr, Calgary, AB, Canada; Mayo Clin, Dept Med, Div Hematol Oncol, Jacksonville, FL USA; Cedars Sinai Med Ctr, Dept Med, Div Hematol & Oncol, Los Angeles, CA USA; AstraZeneca, Gaithersburg, MD USA; AstraZeneca, Wilmington, DE USA; Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA; Cornell Univ, Weill Med Coll, New York, NY USA | Kudo, Masatoshi/AAA-9744-2019; tougeron, david/ABF-3217-2020; De Toni, Enrico/C-6496-2008; Cheng, Ann-Lii/ACM-0936-2022; Gasbarrini, Antonio/AAB-8487-2019; Sangro, Bruno/AFW-4106-2022; Lim, Ho Yeong/KBA-8868-2024; Lau, George/AAQ-2085-2021 | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 41 | 16 | SCIE | ONCOLOGY | 2023 | 42.1 | 1.7 | 12 | English | 2023 | 2023-06-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | Lee, Jeeyun; Shergill, Ardaman; Park, Haeseong; Lee, Keun-Wook; Arkenau, Hendrik-Tobias; Kang, Yoon-Koo; Olowokure, Olugbenga Olanrele; Kim, Jong Gwang; Oh, Sung Yong; Oh, Do-Youn; Costin, Dan; Pippas, Andrew William; Chen, Jen-Shi; Chaney, Marya F.; Koustenis, Andrew; Youssoufian, Hagop; Makris, Lukas; Culm, Kerry; Mockbee, Colleen M.; Chau, Ian | Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea; Univ Chicago, Sect Hematol & Oncol, Dept Med, Med Ctr, Chicago, IL USA; Dana Farber Canc Inst, Boston, MA USA; Seoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Seongnam, South Korea; Sarah Cannon Res Inst UK, London, England; Asan Med Ctr, Seoul, South Korea; Univ Cincinnati, Cincinnati, OH USA; Kyungpook Natl Univ, Sch Med, Dept Oncol Hematol, Med Ctr, Daegu, South Korea; Donga Univ Hosp, Seo Gu, South Korea; Seoul Natl Univ Hosp, Med Oncol, Seoul, South Korea; Westchester Inst Treatment Canc & Blood Disorder, White Plains, NY USA; John B Amos Canc Ctr, Columbus, GA USA; Chang Gung Mem Hosp, Dept Hematol Oncol, Taoyuan, Taiwan; Merck & Co Inc, Rahway, NJ USA; OncXerna Therapeut, Waltham, MA USA; Brown Univ, OncXerna Therapeut Inc, Waltham, MA USA; Stathmi Inc, New Hope, PA USA; OncXerna Therapeut Inc, Waltham, MA USA; Royal Marsden NHS Fdn Trust, London, England; Royal Marsden NHS Fdn Trust, Sutton, England | Park, Haeseong/AAL-7982-2021; Chau, Ian/ABC-2023-2020; Kim, Sung-Bae/JXL-8219-2024; Chen, Jen-Shi/GLV-3349-2022; Lee, Jeeyun/I-7171-2015; Kang, Yoon-Koo/ABL-4264-2022; Lee, Juhyung/JQV-8143-2023 | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 41 | 16 | SCIE | ONCOLOGY | 2023 | 42.1 | 1.7 | 0 | English | 2023 | 2023-06-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Post-double lung transplantation survival outcomes of bilateral lung cancer and incidence of post-transplant lung cancer | Lee, Jeeyeon; Yu, Jisang; Schellenberg, Samuel; Chung, Il-Young; Bharat, Ankit; Chae, Young Kwang | Kyungpook Natl Univ Hosp, Daegu, South Korea; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Northwestern Univ, Chicago, IL 60611 USA | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 41 | 16 | SCIE | ONCOLOGY | 2023 | 42.1 | 1.7 | 0 | English | 2023 | 2023-06-01 | 바로가기 | 바로가기 | ||||||||||||||||
| ○ | Meeting Abstract | Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25) | Ahn, Sung Gwe; Kook, Yoonwon; Moon, Hyeong-Gon; Lee, Jeong Eon; Ahn, Jee Hyun; Chae, Heejung; Lee, Jeeyeon; Park, Min Ho; Yoon, Chang Ik; Kang, Taewoo; Youn, Hyun Jo; Yoo, Tae-Kyung; Kim, Hyun-Ah; Kim, Eun-Kyu; Kang, Su Hwan; Lim, Woosung; Lee, Han-Byoel; Han, Wonshik; Park, Yeon Hee | Yonesi Univ, Gangnam Severance Hosp, Seoul, South Korea; Gangnam Severance Hosp, Seoul, South Korea; Seoul Natl Univ, Dept Surg, Coll Med, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea; Yonsei Univ, Dept Surg, Coll Med, Seoul, South Korea; Natl Canc Ctr, Dept Internal Med, Goyang, South Korea; Kyungpook Natl Univ Hosp, Daegu, South Korea; Chonnam Nat Univ Med Sch, Dept Surg, Gwangju, South Korea; Chonnam Nat Univ Hwasun Hosp, Gwangju, South Korea; Catholic Univ Korea, Seoul, South Korea; Pusan Natl Univ Hosp, Busan Canc Ctr, Biomed Res Inst, Breast Canc Clin, Busan, South Korea; Jeonbuk Natl Univ, Dept Surg, Med Sch, Jeonju, South Korea; Asan Med Ctr, Seoul, South Korea; Korea Canc Ctr Hosp, Seoul, South Korea; Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea; Yeungnam Univ, Coll Med, Dept Surg, Med Ctr, Daegu, South Korea; Ewha Womans Univ, Med Ctr, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea | Kim, Chang Gon/IAP-6721-2023; Moon, Hyeong-Gon/G-7724-2011; Kim, Eun-Kyu/LNQ-3974-2024; Lee, Dong-Hyeon/AAM-3893-2021; Lee, Jongseung/AER-7002-2022; Ahn, Sung Gwe/AFD-8122-2022 | JOURNAL OF CLINICAL ONCOLOGY | J CLIN ONCOL | 0732-183X | 1527-7755 | 41 | 16 | SCIE | ONCOLOGY | 2023 | 42.1 | 1.7 | 1 | English | 2023 | 2023-06-01 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Real-world experience of atezolizumab plus bevacizumab combination treatment in high risk patients with advanced hepatocellular carcinoma | Hwang, Sangyoun; Woo, Hyun Young; Heo, Jeong; Kim, Hyung Jun; Park, Young Joo; Yi, Kiyoun; Lee, Yu Rim; Park, Soo Young; Jang, Byoung Kuk; Chung, Woo Jin; Tak, Won Young | Dongnam Inst Radiol & Med Sci, Busan, South Korea; Pusan Natl Univ Hosp, Busan, South Korea; Kyungpook Natl Univ Hosp, Daegu, South Korea; Keimyung Univ, Dongsan Hosp, Daegu, South Korea | Heo, Jeong/MHQ-1390-2025 | jheo@pusan.ac.kr; | JOURNAL OF HEPATOLOGY | J HEPATOL | 0168-8278 | 1600-0641 | 78 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2023 | 26.8 | 1.7 | 0 | English | 2023 | 2023-06 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | Meeting Abstract | Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: post-treatment follow-up | Yuen, Man-Fung; Lim, Young-Suk; Yoon, Ki Tae; Lim, Tien Huey; Heo, Jeong; Tangkijvanich, Pisit; Tak, Won Young; Thanawala, Vaidehi; Cloutier, Daniel; Mao, Shenghua; Arizpe, Andre; Cathcart, Andrea; Gupta, Sneha V.; Hwang, Carey; Gane, Edward J. | Queen Mary Hosp, Sch Clin Med, Dept Med, London, England; Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China; Pusan Natl Univ, Yangsan Hosp, Liver Ctr, Yangsan, South Korea; Pusan Natl Univ, Liver Ctr, Yangsan Hosp, Yangsan, South Korea; Pusan Natl Univ, Coll Med, Dept Internal Med, Div Gastroenterol & Hepatol, Yangsan, South Korea; Middlemore Hosp, Dept Gastroenterol & Hepatol, Auckland, New Zealand; Pusan Natl Univ, Coll Med, Dept Internal Med, Busan, South Korea; Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea; Chulalongkorn Univ, Fac Med, Bangkok, Thailand; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Div Gastroenterol & Hepatol, Dept Internal Med,Sch Med, Daegu, South Korea; VIR Biotechnol Inc, San Francisco, CA USA; Univ Auckland, Dept Med & Hlth Sci, Auckland, New Zealand | Yuen, Richard Man Fung/C-4466-2009; Gane, Edward/AGN-7071-2022; Lim, Young-Suk/AFQ-5165-2022; Heo, Jeong/MHQ-1390-2025 | mfyuen@hku.hk; | JOURNAL OF HEPATOLOGY | J HEPATOL | 0168-8278 | 1600-0641 | 78 | SCIE | GASTROENTEROLOGY & HEPATOLOGY | 2023 | 26.8 | 1.7 | 3 | English | 2023 | 2023-06 | 바로가기 | 바로가기 | |||||||||||||||
| ○ | ○ | Article | Schottky barrier modulation of bottom contact SnO2 thin-film transistors via chloride-based combustion synthesis | The enhanced carrier flow at the interface between Au and SnO2 semiconductors, which initially form Schottky contacts, is realized using chloride-based combustion synthesis. Chloride-based combustion sys-tems can achieve chlorine (Cl) doping effects as well as conversion to crystalline SnO2 films at clearly lower temperatures ( -250 degrees C) than conventional precursors. Due to the Cl doping effect, the high carrier concentration can induce thin potential barriers at the metal/semiconductor (MS) junctions, resulting in carrier injection by tunneling. As a result, compared to conventional SnO2 thin-film transistors, the de-vices fabricated by combustion synthesis exhibit significantly improved electrical performance with field-effect mobility of 6.52 cm2/Vs (-13 times), subthreshold swing of 0.74 V/dec, and on/off ratio of-107 below 300 degrees C. Furthermore, because of the enhanced tunneling carriers induced by the narrowed barrier width, the Schottky barriers are significantly reduced from 0.83 to 0.29 eV (65% decrease) at 250 degrees C and from 0.42 to 0.17 eV (60% decrease) at 400 degrees C. Therefore, chloride-based combustion synthesis can con-tribute to developing SnO2-based electronics and flexible devices by achieving both high-quality oxide films and improved current flow at the MS interface with low-temperature annealing.(c) 2023 Published by Elsevier Ltd on behalf of The editorial office of Journal of Materials Science & Technology. | Jang, Bongho; Lee, Junhee; Kang, Hongki; Jang, Jaewon; Kwon, Hyuk-Jun | DGIST, Dept Elect Engn & Comp Sci, Daegu 42988, South Korea; Kyungpook Natl Univ, Sch Elect & Elect Engn, Daegu 41566, South Korea; Kyungpook Natl Univ, Sch Elect Engn, Daegu 41566, South Korea; DGIST, Convergence Res Adv Ctr Olfact, Daegu 42988, South Korea | ; Kang, Hongki/AFM-2155-2022 | 57194718232; 57364964200; 36158223200; 57194107504; 57298892000 | hj.kwon@dgist.ac.kr; | JOURNAL OF MATERIALS SCIENCE & TECHNOLOGY | J MATER SCI TECHNOL | 1005-0302 | 1941-1162 | 148 | SCIE | MATERIALS SCIENCE, MULTIDISCIPLINARY;METALLURGY & METALLURGICAL ENGINEERING | 2023 | 11.2 | 1.7 | 0.63 | 2025-06-25 | 5 | 5 | SnO 2; Combustion; Sol-gel; Schottky contact; Thin-film transistors | OXIDE; PERFORMANCE; DEVICE | Combustion; Schottky contact; SnO<sub>2</sub>; Sol-gel; Thin-film transistors | Carrier concentration; Chlorine compounds; Combustion synthesis; Field effect transistors; Flexible electronics; Oxide films; Schottky barrier diodes; Semiconductor doping; Sol-gels; Temperature; Thin film circuits; Thin films; Bottom contacts; C. thin film transistor (TFT); Carrier flow; Chlorine doping; Combustion systems; Doping effects; Lows-temperatures; Schottky barriers; Schottky contacts; Sol'gel; Thin film transistors | English | 2023 | 2023-06-10 | 10.1016/j.jmst.2022.11.025 | 바로가기 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: